Drug Shortages Put Compounding Pharmacies in the Policy Spotlight

Persistent drug shortages are prompting lawmakers to reassess the role compounding facilities play in maintaining continuity of care.

America’s drug-supply chain has been running on thin margins for years. The cracks show up everywhere through antibiotics on backorder, hospital-administered medications rationed, and high-utilization generics that vanish from shelves without much warning. And millions of patients feel those gaps long before policymakers do.

This strain is especially visible in the ongoing shortage of GLP-1 medications such as tirzepatide. These therapies often get dismissed as lifestyle drugs, but they are nothing of the sort for the patients who rely on them to manage chronic conditions. For thousands managing obesity, insulin resistance, or Type 2 diabetes, consistent access is necessary to prevent clinical setbacks. So when a shortage hits, their entire disease-management plan is disrupted. Weight rebounds quickly, glycemic control deteriorates, cardiovascular risk rises, and more. For these patients, the consequences are clinical, not cosmetic.

When the United States supply chain cannot meet demand, patients are the ones left suffering, and that suffering takes several forms. It begins with their health deteriorating when continuity of care is disrupted. It continues with financial strain when insurers refuse to cover access through alternative channels. And when those avenues close, desperation sets in and many begin looking elsewhere, including crossing international borders to secure treatment. Others turn to gray-market sources online where unverified products and real safety risks are common. This is the point in the story where compounding pharmacies enter the conversation, even though most Americans do not yet understand why.

For many, the phrase “compounding pharmacy” still conjures an image of a corner shop where a pharmacist uses a mortar and pestle to prepare individualized medication batches. That is one form of compounding, but it is not the form that sustains patient access during national shortages. Across the country there are large, highly regulated 503A and 503B compounding facilities that operate at scale and can produce critical medications in high throughput with FDA-inspected quality controls. 503A facilities prepare medications based on individual prescriptions, while 503B facilities function as outsourcing manufacturers that produce medications in larger batches for hospitals, clinics, and pharmacies. Together, they provide a safety valve for the healthcare system. These facilities exist for the purpose of providing continuity of care when commercial manufacturers cannot meet the nation’s medical demand.

That function is becoming more important as shortages grow more frequent and more disruptive. Patients who lose access to the therapies that stabilize their conditions face preventable complications that have nothing to do with personal choice and everything to do with supply constraints. Providers who care for those patients face limited options when commercial inventory disappears. Compounding facilities are built to serve as a backstop, yet most of the public remains unaware that this infrastructure even exists.

Compounding pharmacies cannot simply produce any medication whenever there is a shortage. For 503A and 503B facilities, production authority is set by FDA rules and by the Bulk Drug Substances Lists, which identify the ingredients that may be used in compounding. If a therapy is not on those lists, even when it is in nationwide shortage, compounding pharmacies cannot step in until the FDA completes its review and reaches a decision. That review process can move slowly, even when patient demand is urgent, and even when gaps in the commercial supply chain are well documented.

This is why tirzepatide has become a policy flashpoint. The drug’s shortage has lasted long enough and affected enough patients that members of Congress, health-policy advisors, patient-advocacy groups, and compounding pharmacies are urging the FDA to prioritize its evaluation for addition to the 503B list. The goal is straightforward and involves maintaining continuity of care within a regulated United States channel rather than pushing patients toward gray-market imports or medical deterioration. Policymakers are beginning to recognize that the current system leaves too many patients exposed when commercial supply cannot keep pace with medical need.

This debate is not limited to GLP-1s. The same structural shortages affect antibiotics, cancer medications, ADHD treatments, and many generics that rarely make headlines but matter to the people who depend on them. These shortages are not isolated events. They reflect a system pushed to its limit, one in which a single disruption can cascade through hospitals, clinics, and pharmacies. A modern drug-supply chain needs a safety valve, and compounding pharmacies are the one system already built to provide it, provided that regulators empower them to do so responsibly.

What is beginning to happen on Capitol Hill is a recognition that compounding is not a fringe practice. It is an essential part of America’s healthcare infrastructure. The more the public understands this reality, the harder it becomes to dismiss compounding pharmacies as niche operators or to treat their role as an afterthought when shortages occur. A stable drug-supply chain requires redundancy, and compounding pharmacies represent one of the few areas where added capacity already exists and can be mobilized.

Tirzepatide happens to be the case study animating the discussion today. Though, the underlying issue runs deeper. The national drug-supply system needs additional capacity, additional redundancy, and a policy framework that reflects how patients actually experience shortages. Compounding pharmacies can fill that void. The question now is whether federal policy will allow them to.